Targeting immunometabolism in host-directed therapies to fungal disease

Clin Exp Immunol. 2022 Jun 11;208(2):158-166. doi: 10.1093/cei/uxab014.

Abstract

Fungal infections affect over a billion people and are responsible for more than 1.5 million deaths each year. Despite progress in diagnostic and therapeutic approaches, the management of severe fungal infections remains a challenge. Recently, the reprogramming of cellular metabolism has emerged as a central mechanism through which the effector functions of immune cells are supported to promote antifungal activity. An improved understanding of the immunometabolic signatures that orchestrate antifungal immunity, together with the dissection of the mechanisms that underlie heterogeneity in individual immune responses, may therefore unveil new targets amenable to adjunctive host-directed therapies. In this review, we highlight recent advances in the metabolic regulation of host-fungus interactions and antifungal immune responses, and outline targetable pathways and mechanisms with promising therapeutic potential.

Keywords: antifungal immunity; fungal disease; host-directed therapy; immunometabolism; immunotherapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents* / therapeutic use
  • Humans
  • Immunotherapy
  • Mycoses* / drug therapy

Substances

  • Antifungal Agents